Therapy insight: Adipocytokines in metabolic syndrome and related cardiovascular disease

Nature Clinical Practice Cardiovascular Medicine

Volumn 3, Issue 1, 2006, Pages 35-42

  Matsuzawa, Yuji ^a  

^a SUMITOMO HOSPITAL   (Japan)

Author keywords

Adipocytokine; Adiponectin; PAI 1; Visceral fat; Visfatin

Indexed keywords

2,4 THIAZOLIDINEDIONE; ADIPOCYTOKINE; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; CARDIOVASCULAR DISEASE; CELL FUNCTION; CYTOKINE RELEASE; DIABETES MELLITUS; ENDOCRINE CELL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID STORAGE; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; NUTRITIONAL STATUS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; VASCULAR DISEASE;

ADIPONECTIN; ADIPOSE TISSUE; CARDIOVASCULAR DISEASES; CYTOKINES; HUMANS; METABOLIC SYNDROME X; RISK FACTORS;

EID: 30544439060     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0380     Document Type: Review

References (57)

1. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607
2. Kaplan NM (1989) The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149: 1514-1520
3. DeFronzo RA (1991) Insulin resistance syndrome. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173-194
4. International Diabetes Federation (online 14 April 2005) A new worldwide definition of the metabolic syndrome [http://www.idf.org/home/index.cfm?unode=32EF2063-B966-468F- 928C-A5682A4E3910] (accessed 13 September 2005)
5. Matsuzawa Y (1997) Pathophysiology and molecular mechanism of visceral fat syndrome: The Japanese case. Diabetes Metab Rev 13: 3-13
6. Despres JP et al. (1989) Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes 38: 304-309
7. Maeda K et al. (1997) Analysis of expression profile of genes in the human adipose tissue. Gene 190: 227-235
8. Matsuzawa Y et al. (2004) Adiponectin and metabolic syndrome. Arteroscler Thromb Vasc Biol 24: 29-33
9. Maeda K et al. (1996) cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221: 286-289
10. Vague J (1956) The degree of masculine differentiation of obesities: A factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease. Am J Clin Nutr 4: 20-34
11. Fujioka S et al. (1987) Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36: 54-59
12. Hulthe J et al. (2003) Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: Atherosclerosis and insulin resistance study. Metabolism 52: 1612-1614
13. Evans DJ et al. (1984) Relationship between skeletal muscle insulin resistance, insulin-mediated glucose disposal and insulin binding: Effect of obesity and body fat topography. J Clin Invest 74: 1515-1525
14. Yamashita S et al. (1996) Insulin resistance and body fat distribution. Diabetes Care 19: 287-291
15. Kanai H et al. (1990) Close correlation of intraabdominal fat accumulation to hypertension in obese women. Hypertension 16: 484-490
16. Larson B et al. (1984) Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13 year follow up of participants in study of men born in 1913. BMJ 288: 1401-1410
17. Nakamura T et al. (1994) Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107: 239-246
18. Nakamura T et al. (1997) Importance of intraabdominal fat accumulation to coronary atherosclerosis in heterozygous familial hypercholesterolaemia. Int J Obes Relat Metab Disord 21: 580-586
19. Nakajima T et al. (1989) Correlation of intraabdominal fat accumulation and left ventricular performance in obesity. Am J Cardiol 64: 369-373
20. Shinohara E et al. (1997) Visceral fat accumulation as an important risk factor for obstructive sleep apnoea syndrome in obese subjects. J Intern Med 241: 11-18
21. Funahashi T et al. (1999) Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Inter Med 38: 202-206
22. Uysal KT et al. (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 389: 610-614
23. Shimomura I et al. (1996) Enhanced expression of PAI-1 in visceral fat: Possible contribution to vascular disease in obesity. Nat Med 2: 800-803
24. Matsumoto S et al. (2002) Increased plasma HB-EGF associated with obesity and coronary artery disease. Biochem Biophys Res Commun 292: 781-786
25. Matsuzawa Y (2005) Adipocytokines and metabolic syndrome. Semin Vasc Med 5: 34-39
26. Cigolini M et al. (1996) Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 16: 368-374
27. Fukuhara A et al. (2005) Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426-430
28. Hu E et al. (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271: 10697-10703
29. Sherer EP et al. (1995) A novel serum protein similar to C1q produced exclusively in adipocytes. J Biol Chem 270: 26746-26749
30. Arita Y et al. (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83
31. Halleux CM et al. (2001) Secretion and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 288: 1102-1107
32. Maeda N et al. (2001) PPARγ ligands increase expression and plasma concentration of adiponectin, an adipose-derived protein. Diabetes 50: 2094-2099
33. Hotta K et al. (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595-1599
34. Stefan N et al. (2002) Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation and low plasma concentration precedes a decrease in whole body insulin sensitivity in humans. Diabetes 51: 1884-1888
35. Lindsay RS et al. (2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360: 57-58
36. Maeda N et al. (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8: 731-737
37. Tomas E et al. (2002) Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: Acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 90: 16309-16313
38. Iwashima Y et al. (2004) Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43: 1318-1323
39. Ouchi N et al. (2003) Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42: 231-234
40. Ouchi N et al. (1999) Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation 100: 2473-2476
41. Zoccali C et al. (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13: 134-141
42. Kumada M et al. (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23: 85-89
43. Pischon T et al. (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291: 1730-1737
44. Kondo H et al. (2002) Association of adiponectin mutation with type 2 diabetes: A candidate gene for the insulin resistance syndrome. Diabetes 51: 2325-2328
45. Okamoto Y et al. (2002) Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 26: 2767-2770
46. Matsuda M et al. (2002) Role of adiponectin in preventing vascular stenosis: The missing link of adipo-vascular axis. J Biol Chem 277: 37487-37491
47. Okamoto Y et al. (2000) An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 32: 47-50
48. Ouchi N et al. (2000) Adiponectin, adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through c-AMP dependent pathway. Circulation 102: 1296-1301
49. Arita Y et al. (2002) Adipocyte-derived plasma protein, adiponectin, acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105: 2893-2898
50. Ouchi N et al. (2001) Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103: 1057-1063
51. Kumada M et al. (2004) Adiponectin specifically increases tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109: 2046-2049
52. Shibata R et al. (2004) Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10: 1384-1389
53. Kobayashi H et al. (2004) Selective suppression of endothelial cell apotosis by high molecular weight form of adiponectin. Circ Res 94: e27-e31
54. Fisher FF et al. (2005) Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian Males. Diabetologia 48: 1084-1087
55. Hug C et al. (2004) T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 101: 10308-10313
56. Yamauchi T et al. (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423: 762-769
57. Nishizawa H et al. (2002) Small heterodimer partner, an orphan nuclear receptor, augments peroxisome proliferator-activated receptor γ transactivation. J Biol Chem 277: 1586-1592